Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
BioNTech SE (22UA.F)
Mainz, DE
BioNTech SE is a biotechnology firm dedicated to the research, development, and marketing of immunotherapies for oncology and a spectrum of infectious diseases. Its diverse product pipeline features several FixVac candidates, including BNT111, currently undergoing Phase II clinical trials for advanced melanoma; BNT112, in Phase I/IIa development for prostate cancer; BNT113, progressing through Phase II for HPV-positive head and neck cancers; BNT114, in Phase I for triple-negative breast cancer; BNT115, also in Phase I for ovarian cancer; and BNT116, a preclinical asset targeting non-small cell lung cancer. Further expanding its oncology focus, BioNTech is advancing neoantigen-specific immunotherapies like Autogene cevumeran (BNT122), which is in Phase II trials for first-line melanoma and Phase 1a/1b trials for multiple solid tumors. The company's mRNA intratumoral immunotherapy, SAR441000, is undergoing Phase I evaluation for solid tumors, complemented by additional neoantigen-specific programs BNT141 and BNT142, both in Phase I clinical studies for various solid malignancies. The firm's portfolio also encompasses RiboCytokines, such as BNT151, BNT152, and BNT153, designed to treat solid tumors. Chimeric antigen receptor T cell (CAR T) immunotherapies include BNT211, aimed at multiple solid tumors, and BNT221 for other cancer types. Additionally, checkpoint immunomodulators GEN1046 and GEN1042 are in Phase I/II clinical development for solid tumor indications. Beyond these, BioNTech is developing BNT321, an IgG1 monoclonal antibody in Phase II trials for pancreatic cancer, and BNT411, a small molecule immunomodulator candidate for solid tumors. The company is also actively involved in the creation of prophylactic vaccines for COVID-19 and Influenza, alongside other infectious disease immunotherapies and therapies for rare diseases involving protein replacement. BioNTech maintains strategic alliances with several prominent pharmaceutical and biotechnology entities, including Genentech, Inc., Sanofi S.A., Genmab A/S, Pfizer Inc., Shanghai Fosun Pharmaceutical (Group) Co., Ltd., and Regeneron Pharmaceuticals, Inc. Established in 2008, BioNTech SE's corporate headquarters are located in Mainz, Germany.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -1.68% | -1.38% | -0.82% | -12.24% | -18.83% | -4.31% | -8.94% | -18.96% | -49.47% | +508.33% | +508.33% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Biotechnology: +1.6%+0.2% Q1'26: -35.4% (vs Q1'25)
-
EPS growth Biotechnology: +29.7%-63.2% Q1'26: -21.4% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%-0.1% Q1'26: -409.7% (vs Q1'25)
-
EBIT margin Biotechnology: +0.0%-22.6% Q1'26: -471.5% (vs Q1'25)
-
ROIC Biotechnology: -16.1%-13.4% ★ Q1'26: -47.8% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+0.5% ★ Q1'26: +5.4% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-1.04× Q1'26: -0.17× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 16 Rev. Ana. 1 EPS Ana. |
Dec 2027 16 Rev. Ana. 1 EPS Ana. |
Dec 2028 14 Rev. Ana. 1 EPS Ana. |
Dec 2029 15 Rev. Ana. 1 EPS Ana. |
Dec 2030 15 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
108.59M
est: 110.82M (-2.0%)
|
482.33M
est: 367.81M (+31.1%)
|
18.98B
est: 17.12B (+10.8%)
|
17.31B
est: 16.68B (+3.8%)
|
3.82B
est: 4.19B (-8.8%)
|
2.75B
est: 2.66B (+3.6%)
|
2.76B
est: 2.72B (+1.4%)
|
2.18B
2.03B – 2.35B
-19.7% YoY
|
2.26B
1.45B – 3.00B
+3.4% YoY
|
2.68B
2.10B – 3.23B
+18.7% YoY
|
2.81B
2.20B – 3.39B
+4.8% YoY
|
3.67B
2.86B – 4.42B
+30.5% YoY
|
| EBITDA |
-143.41M
est: 35.37M (-505.4%)
|
-97.89M
est: 117.40M (-183.4%)
|
15.73B
est: 5.47B (+187.8%)
|
12.86B
est: 5.32B (+141.6%)
|
1.38B
est: 1.34B (+3.0%)
|
-367.10M
est: 906.23M (-140.5%)
|
-256.27M
est: 927.62M (-127.6%)
|
745.13M
691.80M – 800.72M
-19.7% YoY
|
770.48M
494.21M – 1.03B
+3.4% YoY
|
914.86M
714.87M – 1.10B
+18.7% YoY
|
958.53M
748.99M – 1.16B
+4.8% YoY
|
1.25B
977.35M – 1.51B
+30.5% YoY
|
| EBIT |
-177.70M
est: 30.00M (-692.3%)
|
-133.99M
est: 99.58M (-234.6%)
|
15.65B
est: 4.64B (+237.6%)
|
12.74B
est: 4.51B (+182.1%)
|
1.19B
est: 1.13B (+5.3%)
|
-665.10M
est: 746.42M (-189.1%)
|
-624.10M
est: 764.04M (-181.7%)
|
613.73M
569.81M – 659.51M
-19.7% YoY
|
634.61M
407.06M – 844.40M
+3.4% YoY
|
753.53M
588.81M – 908.57M
+18.7% YoY
|
789.50M
616.91M – 951.93M
+4.8% YoY
|
1.03B
805.00M – 1.24B
+30.5% YoY
|
| Net Income |
-179.17M
est: -177.09M (-1.2%)
|
15.20M
est: -381.66M (+104.0%)
|
10.29B
est: 8.66B (+18.9%)
|
9.43B
est: 8.45B (+11.6%)
|
930.30M
est: 1.03B (-10.0%)
|
-665.30M
est: -799.28M (+16.8%)
|
-1.09B
est: -849.08M (-28.6%)
|
-1.13B
-1.43B – -809.37M
-33.2% YoY
|
-1.15B
-1.46B – -823.91M
-1.8% YoY
|
-893.92M
-1.13B – -639.88M
+22.3% YoY
|
-784.01M
-993.70M – -561.20M
+12.3% YoY
|
-112.39M
-142.45M – -80.45M
+85.7% YoY
|
| SGA |
43.41M
est: 14.13M (+207.2%)
|
108.56M
est: 46.90M (+131.5%)
|
328.90M
est: 2.18B (-84.9%)
|
544.20M
est: 2.13B (-74.4%)
|
557.70M
est: 534.14M (+4.4%)
|
599.00M
est: 353.63M (+69.4%)
|
698.20M
est: 361.97M (+92.9%)
|
290.76M
269.96M – 312.46M
-19.7% YoY
|
300.66M
192.85M – 400.05M
+3.4% YoY
|
357.00M
278.96M – 430.45M
+18.7% YoY
|
374.04M
292.27M – 450.99M
+4.8% YoY
|
488.08M
381.38M – 588.49M
+30.5% YoY
|
| EPS |
-0.85
est: -0.74 (-15.4%)
|
0.06
est: -1.59 (+103.8%)
|
43.87
est: 36.02 (+21.8%)
|
38.08
est: 35.16 (+8.3%)
|
3.87
est: 4.30 (-10.0%)
|
-2.77
est: -3.31 (+16.2%)
|
-4.52
est: -3.51 (-28.7%)
|
-4.68
-5.93 – -3.35
-33.2% YoY
|
-4.76
-6.04 – -3.41
-1.8% YoY
|
-3.70
-4.69 – -2.65
+22.3% YoY
|
-3.24
-4.11 – -2.32
+12.3% YoY
|
-0.47
-0.59 – -0.33
+85.7% YoY
|
| Date | Firm | Previous | New Grade | Action |
|---|---|---|---|---|
| 2026-05-06 | Wells Fargo | Overweight | Overweight | Maintain |
| 2026-04-27 | HC Wainwright & Co. | Buy | Buy | Maintain |
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-08 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-07 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-06 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-05 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-04 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-04-30 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-04-29 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-04-28 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-04-27 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-04-24 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-23 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-22 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-21 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-20 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-17 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-16 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Ugur Sahin | Co-Founder, Chief Executive Officer & Chair of the Management Board | 1M | — |
| Ramon Zapata-Gomez | Chief Financial Officer & Member of Management Board | 1M | male |
| Annemarie Hanekamp | Chief Commercial Officer & Member of Management Board | 897.0K | female |
| James Timothy Patrick Ryan | Chief Legal & Business Officer and Member of the Management Board | 889.0K | — |
| Sierk Poetting | MD, Chief Operating Officer & Member of Management Board | 868.0K | — |
| Sierk Pötting | MD, Chief Operating Officer & Member of Management Board | 868.0K | — |
| Ozlem Tureci | Co-Founder, Chief Medical Officer & Member of Management Board | 841.0K | — |
| Sebastian Kreiter | Senior Vice President of Immunotherapy & Preclinical Research | — | — |
| Siegbert Kloos | Senior Vice President of Global R&D Digital, Datand Informatics | — | male |
| Oliver Henning | Senior Vice President of Operations | — | — |
| Beate Berns | Senior Vice President of Global Human Resources | — | female |
| Douglas Maffei | Vice President of Strategy & Investor Relations | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 22UA.F
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
